dopamine agonists

Summary

Summary: Drugs that bind to and activate dopamine receptors.

Top Publications

  1. ncbi Dopamine agonists in animal models of Parkinson's disease: a systematic review and meta-analysis
    Evelien D M Rooke
    Department of Clinical Neurosciences, Centre for Clinical Brain Sciences, University of Edinburgh, Royal Infirmary of Edinburgh, UK
    Parkinsonism Relat Disord 17:313-20. 2011
  2. pmc Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)
    Claudia Trenkwalder
    Department of Clinical Neurophysiology, University of Goettingen and Paracelsus Elena Klinik, Kassel, Germany
    Mov Disord 26:90-9. 2011
  3. pmc Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration
    Roshan Cools
    Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    J Neurosci 29:1538-43. 2009
  4. pmc Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons
    J K Seamans
    Howard Hughes Medical Institute and Molecular and Computational Neurobiology Laboratory, The Salk Institute, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 98:301-6. 2001
  5. ncbi Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior
    Yukiori Goto
    Department of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
    Nat Neurosci 8:805-12. 2005
  6. pmc Association of dopamine agonist use with impulse control disorders in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, and Parkinson s Disease Research, Education, and Clinical Center, USA
    Arch Neurol 63:969-73. 2006
  7. pmc Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
    Thilo van Eimeren
    Division of Brain, Imaging and Behaviour Systems Neuroscience, BIB SN, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada
    Neuropsychopharmacology 34:2758-66. 2009
  8. pmc Dopamine agonists and risk: impulse control disorders in Parkinson's disease
    Valerie Voon
    Behavioural and Clinical Neurosciences Institute, Department of Experimental Psychology, Downing Site, University of Cambridge, Cambridge CB2 3EB, UK
    Brain 134:1438-46. 2011
  9. ncbi Advances in the treatment of prolactinomas
    Mary P Gillam
    Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Endocr Rev 27:485-534. 2006
  10. pmc Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients
    Nikoletta Bodi
    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    Brain 132:2385-95. 2009

Detail Information

Publications338 found, 100 shown here

  1. ncbi Dopamine agonists in animal models of Parkinson's disease: a systematic review and meta-analysis
    Evelien D M Rooke
    Department of Clinical Neurosciences, Centre for Clinical Brain Sciences, University of Edinburgh, Royal Infirmary of Edinburgh, UK
    Parkinsonism Relat Disord 17:313-20. 2011
    ..In this study we use these tools to describe the reported efficacy of dopamine agonists in animal models of PD.
  2. pmc Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER)
    Claudia Trenkwalder
    Department of Clinical Neurophysiology, University of Goettingen and Paracelsus Elena Klinik, Kassel, Germany
    Mov Disord 26:90-9. 2011
    ..Twenty-four-hour transdermal delivery of rotigotine to PD patients with early-morning motor dysfunction resulted in significant benefits in control of both motor function and nocturnal sleep disturbances...
  3. pmc Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration
    Roshan Cools
    Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    J Neurosci 29:1538-43. 2009
    ..These data demonstrate that the effects of D(2) receptor stimulation on reversal learning in humans depend on task demands and baseline striatal dopamine synthesis capacity...
  4. pmc Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons
    J K Seamans
    Howard Hughes Medical Institute and Molecular and Computational Neurobiology Laboratory, The Salk Institute, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 98:301-6. 2001
    ..By increasing the NMDA component of EPSCs, yet slightly reducing release, D1/D5 receptor activation selectively enhanced sustained synaptic inputs and equalized the sizes of EPSPs in a 20-Hz train...
  5. ncbi Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior
    Yukiori Goto
    Department of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
    Nat Neurosci 8:805-12. 2005
    ..These results suggest that the dynamics of DA release regulate the balance between limbic and cortical drive through activation and inactivation of DA receptor subtypes in the accumbens, and this regulates goal-directed behavior...
  6. pmc Association of dopamine agonist use with impulse control disorders in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, and Parkinson s Disease Research, Education, and Clinical Center, USA
    Arch Neurol 63:969-73. 2006
    ..To determine the frequency and correlates of impulse control disorders (ICDs) in Parkinson disease (PD)...
  7. pmc Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
    Thilo van Eimeren
    Division of Brain, Imaging and Behaviour Systems Neuroscience, BIB SN, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada
    Neuropsychopharmacology 34:2758-66. 2009
    ..Treatment with dopamine agonists (DAs) has been associated with pathological gambling in PD patients...
  8. pmc Dopamine agonists and risk: impulse control disorders in Parkinson's disease
    Valerie Voon
    Behavioural and Clinical Neurosciences Institute, Department of Experimental Psychology, Downing Site, University of Cambridge, Cambridge CB2 3EB, UK
    Brain 134:1438-46. 2011
    ..taking task while performing functional magnetic resonance imaging, we investigated the relationship between dopamine agonists and risk taking in patients with Parkinson's disease with and without impulse control disorders...
  9. ncbi Advances in the treatment of prolactinomas
    Mary P Gillam
    Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Endocr Rev 27:485-534. 2006
    ..Medical therapy with dopamine agonists is highly effective in the majority of cases and represents the mainstay of therapy...
  10. pmc Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients
    Nikoletta Bodi
    Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
    Brain 132:2385-95. 2009
    ..The never-medicated patients were also re-evaluated after 12 weeks of treatment with dopamine agonists. Reward and punishment processing was assessed by a feedback-based probabilistic classification task...
  11. ncbi A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Lancet Neurol 8:929-37. 2009
    ..Among the first options are the dopamine agonists, which are commonly used both as an early monotherapy and as an adjunct therapy to levodopa...
  12. ncbi Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome
    Andrew H Evans
    Reta Lila Weston Institute of Neurological Studies, London, United Kingdom
    Mov Disord 19:397-405. 2004
    ..We believe that this is an underreported, socially disabling phenomenon that is commonly associated with the syndrome of dopamine dysregulation and is phenomenologically distinct from both obsessive-compulsive disorder and mania...
  13. ncbi Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3 beta and a receptor-independent anti-oxidative action
    Yang Yu
    State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
    J Neurochem 104:946-56. 2008
    ....
  14. pmc Differential roles of dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task
    Marie Astrid Pezze
    Department of Experimental Psychology, University of Cambridge, Cambridge, UK
    Neuropsychopharmacology 32:273-83. 2007
    ..The data are discussed in terms of the different functions of NAC dopamine receptors in the processing of information from its different cortico-limbic inputs...
  15. ncbi Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms
    Kuei Y Tseng
    Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, New York 12208, USA
    J Neurosci 24:5131-9. 2004
    ..Thus, the modulatory actions of D1 and D2 receptors on PFC pyramidal cell excitability are mediated by multiple intracellular mechanisms and by activation of GABA(A) receptors, depending on the glutamate receptor subtypes involved...
  16. ncbi Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial
    Werner H Poewe
    Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Lancet Neurol 6:513-20. 2007
    ....
  17. pmc The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence
    Christian A Heidbreder
    Centre of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Pharmaceuticals, 37135 Verona, Italy
    Brain Res Brain Res Rev 49:77-105. 2005
    ..Provided these results can be extrapolated to human drug addicts, they suggest that selective DA D3 receptor antagonists may prove effective as potential pharmacotherapeutic agents to manage drug dependence and addiction...
  18. ncbi Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers
    E R Samuels
    Psychopharmacology Section, Division of Psychiatry, University of Nottingham, Nottingham, UK
    J Psychopharmacol 20:756-70. 2006
    ....
  19. ncbi Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation
    Stephane Thobois
    Universitée Lyon I, Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France
    Brain 133:1111-27. 2010
    ..b>Dopamine agonists were re-introduced if patients developed apathy or depression...
  20. ncbi Dopamine modulates the response of the human amygdala: a study in Parkinson's disease
    Alessandro Tessitore
    Clinical Brain Disorders Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 1384, USA
    J Neurosci 22:9099-103. 2002
    ..Furthermore, consistent with findings in experimental animal paradigms, our results provide in vivo evidence of the role of dopamine in modulating the response of the amygdala to sensory information in human subjects...
  21. ncbi Dopamine modulates excitability of spiny neurons in the avian basal ganglia
    Long Ding
    Department of Zoology, University of Washington, Seattle, Washington 98195 6115, USA
    J Neurosci 22:5210-8. 2002
    ..The diversity of DA actions enables the DA system to fine-tune the dynamics of the song system and allows flexible control over song learning and production...
  22. ncbi In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice
    Eugenii A Rabiner
    GlaxoSmithKline Clinical Imaging Centre, Hammersmith Hospital, London, UK
    Synapse 63:782-93. 2009
    ..The midbrain is thus an excellent target region to examine D3 receptor occupancy with [(11)C]-(+)-PHNO PET in vivo...
  23. ncbi Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade
    Takeshi Kihara
    Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    J Neurosci Res 70:274-82. 2002
    ....
  24. ncbi Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis
    Mohamed A F M Youssef
    Department of Obstetrics and Gynaecology, Cairo University, Cairo, Egypt
    Hum Reprod Update 16:459-66. 2010
    Recently, dopamine agonists were proposed as a prophylactic treatment for ovarian hyperstimulation syndrome (OHSS) in women at high risk in IVF/ICSI treatment cycles.
  25. ncbi Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation
    Stacy A Castner
    Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Neurosci 24:1446-50. 2004
    ....
  26. ncbi Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature
    Stephane Thobois
    Hopital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France
    Clin Ther 28:1-12. 2006
    ..However, the equivalence of doses of dopamine receptor agonists before and after switching drugs remains empirical because few clinical trials have addressed this issue...
  27. pmc The risky business of dopamine agonists in Parkinson disease and impulse control disorders
    Daniel O Claassen
    Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
    Behav Neurosci 125:492-500. 2011
    ..disease (PD), impulse control disorder (ICD) can result from dopaminergic medication use, particularly dopamine agonists (DAA)...
  28. ncbi Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis
    William L Baker
    School of Pharmacy, University of Connecticut, CT, USA
    Parkinsonism Relat Disord 15:287-94. 2009
    Our objective was to perform a meta-analysis of randomized controlled trials of dopamine agonists (DA) as monotherapy as well as adjunctive therapy for the early treatment of Parkinson's disease (PD)...
  29. pmc Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD
    T van Eimeren
    Division of Brain, Imaging and Behaviour Systems Neuroscience, BIB SN, Toronto Western Research Institute, University of Toronto, Canada
    Neurology 75:1711-6. 2010
    Some patients with Parkinson disease (PD) develop pathological gambling when treated with dopamine agonists (DAs)...
  30. ncbi Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management
    Sean S O'Sullivan
    Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, London, England
    CNS Drugs 23:157-70. 2009
    ..considered the most potent trigger for DDS in Parkinson's disease, but subcutaneous apomorphine and oral dopamine agonists may also be responsible...
  31. ncbi Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease
    Francesca Romana Pezzella
    Department of Neurological Sciences, La Sapienza University, Rome, Italy
    Mov Disord 20:77-81. 2005
    ..study showed a significant correlation between HHD and a previous history of mood disorders, and the use of dopamine agonists, either in monotherapy or in combination...
  32. ncbi Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation
    H Y Wang
    Department of Pharmacology, Medical College of Pennsylvania, Philadelphia 19129, USA
    Mol Pharmacol 48:988-94. 1995
    ..The data provide evidence to suggest that in addition to coupling to Gs/adenylyl cyclase, D1-like dopamine sites that couple to Gq may mediate dopamine-stimulated formation of inositol phosphates in the rat striatum...
  33. ncbi Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study
    Peter A LeWitt
    Clinical Neuroscience Center, Southfield, MI 48034, USA
    Neurology 68:1262-7. 2007
    ..In patients experiencing motor fluctuations, a major treatment challenge is the reduction of "off" time, particularly upon awakening. Rotigotine (Neupro) is a novel dopaminergic agonist with 24-hour transdermal delivery...
  34. ncbi Dopaminergic modulation of visual-spatial working memory in Parkinson's disease
    Alberto Costa
    IRCCS, Fondazione Santa Lucia, Universita di Roma Tor Vergata, Italia
    Dement Geriatr Cogn Disord 15:55-66. 2003
    ..Instead, L-dopa administration had a ameliorative effect on accuracy and reaction times in both visual-spatial and visual-object tasks. These results highlight the role of dopamine in the modulation of the WM function in PD patients...
  35. ncbi A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol
    Michael J Frank
    Department of Psychology and Program in NeuroscienceUniversity of Arizona, Tucson, AZ 85721, USA
    Behav Neurosci 120:497-517. 2006
    ..Drug effects interacted with baseline working memory span in all tasks. Taken together, the results support a unified account of the role of dopamine in modulating cognitive processes that depend on the basal ganglia...
  36. ncbi Physiology and pathology of ovarian hyperstimulation syndrome
    Raul Gomez
    Instituto Universitario IVI, Universidad de Valencia, Valencia, Spain
    Semin Reprod Med 28:448-57. 2010
    ..Pharmaco-prevention through dopamine agonists is effective only in nonpregnant high-risk OHSS women...
  37. pmc Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes
    S Gines
    Department of Biochemistry and Molecular Biology, University of Barcelona, 08028 Barcelona, Spain
    Proc Natl Acad Sci U S A 97:8606-11. 2000
    ....
  38. ncbi Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients
    J Kreutzer
    Department of Neurosurgery, University of Erlangen Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    Eur J Endocrinol 158:11-8. 2008
    Medical therapy with dopamine agonists (DA) is the primary treatment of choice in most patients with prolactinomas. 'Classical' surgical indications are intolerance or lack of efficiency of DA therapy...
  39. ncbi A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly
    Shlomo Melmed
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 90:4405-10. 2005
    ....
  40. ncbi Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis
    Olaf M Dekkers
    Department of Endocrinology and Metabolic Diseases, C4 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Endocrinol Metab 95:43-51. 2010
    b>Dopamine agonists are the treatment of choice for prolactinomas and symptomatic idiopathic hyperprolactinemia. However, the optimal treatment strategy and treatment duration is not clear in all details.
  41. ncbi Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists
    Steven P Presgraves
    Molecular and Cellular Biology Graduate Group, Arizona State University, Tempe, AZ, USA
    Neurotox Res 5:579-98. 2004
    ..Further characterization of the neuroprotective effects of DA agonists in this model system can provide unique information about DA receptor dependent and independent mechanisms of neuroprotection...
  42. pmc D2 dopamine receptors recruit a GABA component for their attenuation of excitatory synaptic transmission in the adult rat prefrontal cortex
    Kuei Y Tseng
    Center for Neuropharmacology and Neuroscience, Albany Medical College MC 136, Albany, New York 12208, USA
    Synapse 61:843-50. 2007
    ..To test the functional impact of this change, we investigated the effects of dopamine agonists on PFC excitatory synaptic transmission with whole-cell recordings from deep-layer pyramidal neurons in ..
  43. ncbi Synergistic requirements for the induction of dopaminergic D1/D5-receptor-mediated LTP in hippocampal slices of rat CA1 in vitro
    Sheeja Navakkode
    Leibniz Institute for Neurobiology, Department of Neurophysiology, Magdeburg, Germany
    Neuropharmacology 52:1547-54. 2007
    ..e. NMDA-receptor activation. We provide first evidence that a synergistic role of D1/D5- as well as NMDA-receptor-function is required in mediating processes relevant for the maintenance of this protein synthesis-dependent potentiation...
  44. pmc Single dose of a dopamine agonist impairs reinforcement learning in humans: evidence from event-related potentials and computational modeling of striatal-cortical function
    Diane L Santesso
    Department of Psychology, Harvard University, Cambridge, MA 02138, USA
    Hum Brain Mapp 30:1963-76. 2009
    ..These preliminary findings offer important insights on the role of phasic DA signals on reinforcement learning in humans and provide initial evidence regarding the spatiotemporal dynamics of brain mechanisms underlying these processes...
  45. ncbi Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation
    Sasha E B Gibbs
    University of California, Berkeley, California, USA
    Cogn Affect Behav Neurosci 5:212-21. 2005
    ..Individual differences in PFC dopamine receptor concentration may thus underlie the behavioral effects of dopamine stimulation on working memory function...
  46. pmc Dopamine agonist increases risk taking but blunts reward-related brain activity
    Jordi Riba
    Department of Neuropsychology, University of Magdeburg, Magdeburg, Germany
    PLoS ONE 3:e2479. 2008
    ....
  47. pmc Dopamine modulation of GABA tonic conductance in striatal output neurons
    Megan J Janssen
    Department of Physiology and Biophysics, Georgetown University School of Medicine, Washington, DC 20007, USA
    J Neurosci 29:5116-26. 2009
    ..Our results suggest that distinct phosphorylation of beta3-subunits may cause larger tonic current in D2+ striatopallidal MSNs, and proper intracellular conditions can reveal tonic current in D1+ cells...
  48. ncbi The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery
    Rosario Pivonello
    Department of Molecular and Clinical, Endocrinology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 94:223-30. 2009
    The role of dopamine agonists in the treatment of Cushing's disease (CD) has been previously debated.
  49. ncbi Dopamine modulates inwardly rectifying potassium currents in medial prefrontal cortex pyramidal neurons
    Yan Dong
    Departments of Cellular and Molecular Pharmacology and Neuroscience, Finch University of Health Sciences The Chicago Medical School, North Chicago, Illinois 60064, USA
    J Neurosci 24:3077-85. 2004
    ....
  50. ncbi Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis
    R Talati
    University of Connecticut School of Pharmacy, Storrs, CT, USA
    Int J Clin Pract 63:613-23. 2009
    ....
  51. ncbi Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study
    Roberto Cavallaro
    Department of Neuropsychiatric Sciences, San Raffaele Scientific Institute Hospital, Vita Salute University Medical School, Via Stamira d Ancona 20, 20127 Milan, Italy
    J Clin Psychiatry 65:187-90. 2004
    ..This pilot study aimed to evaluate the efficacy and tolerability of a low dose of cabergoline, a D(2) agonist, in the treatment of risperidone-induced hyperprolactinemia...
  52. ncbi Pramipexole in psychiatry: a systematic review of the literature
    Chris B Aiken
    Department of Psychiatry, Wake Forest University School of Medicine, Winston Salem, NC, USA
    J Clin Psychiatry 68:1230-6. 2007
    ..To assess the risks and benefits of pramipexole in psychiatric populations...
  53. ncbi Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women
    Petra Kok
    Department of General Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
    Am J Physiol Endocrinol Metab 291:E1038-43. 2006
    ..Thus these results imply that short-term bromocriptine treatment ameliorates various components of the metabolic syndrome while it shifts energy balance away from lipogenesis in obese humans...
  54. pmc Direct inhibition of substantia gelatinosa neurones in the rat spinal cord by activation of dopamine D2-like receptors
    Akihiro Tamae
    Department of Physiology, Faculty of Medicine, Saga University, Saga 849 8501, Japan
    J Physiol 568:243-53. 2005
    ..This may be a possible mechanism for antinociception by the descending dopaminergic pathway...
  55. pmc Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease
    Scott A Wylie
    Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Cogn Neurosci 24:1709-24. 2012
    ..b>Dopamine agonists improve motor symptoms of PD but can also provoke impulsive-compulsive behaviors (ICB)...
  56. ncbi Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both
    Michal J Besser
    Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel
    J Neuroimmunol 169:161-71. 2005
    ....
  57. ncbi The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders
    P Sokoloff
    INSERM, Unité de Neurobiologie et Pharmacologie, Moléculaire U573, Centre Paul Broca, 2ter rue d Alesia, 75014 Paris, France
    CNS Neurol Disord Drug Targets 5:25-43. 2006
    ..These data allow us to propose novel treatment options in PD, schizophrenia and drug addiction, which are awaiting evaluation in clinical trials...
  58. ncbi Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway
    Hirokazu Hara
    Department of Clinical Pharmaceutics, Gifu Pharmaceutical University, Gifu, Japan
    J Neurosci Res 84:860-6. 2006
    ..Taken together, our findings suggest that not only the function as a radical scavenger but also the function as an Nrf2-ARE pathway activator may be involved in the neuroprotective effects of Apo...
  59. ncbi Voltage-dependent block of N-methyl-D-aspartate receptors by dopamine D1 receptor ligands
    Changhai Cui
    Blanchette Rockefeller Neurosciences Institute, A and R Building, 3rd Floor, 9601 Medical Center Drive, Rockville, MD 20850, USA
    Mol Pharmacol 70:1761-70. 2006
    ..Our results suggest that the direct inhibition of NMDA receptors by dopamine D1 receptor ligands is due to the channel pore block rather than receptor-receptor interactions...
  60. ncbi Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Nat Clin Pract Neurol 2:382-92. 2006
    ..dopaminergic agents are associated with a decreased risk of motor complications compared with short-acting dopamine agonists or levodopa formulations...
  61. ncbi Prevalence of repetitive and reward-seeking behaviors in Parkinson disease
    V Voon
    Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 1428, USA
    Neurology 67:1254-7. 2006
    ..4%. Compulsive shopping was 0.7%. Combined with our pathologic gambling data, the lifetime prevalence of these behaviors was 6.1% and increases to 13.7% in patients on dopamine agonists.
  62. ncbi Dopamine D(4) receptor activation decreases the expression of mu-opioid receptors in the rat striatum
    Belen Gago
    Department of Cell Biology, School of Science, University of Malaga, 29071 Malaga, Spain
    J Comp Neurol 502:358-66. 2007
    ..Increasing evidence has demonstrated that the islands in the striatum play a critical role in habit acquisition during drug addiction. D(4) R/MOR interactions could be crucial in such processes...
  63. ncbi Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability
    Wolfgang Oertel
    Department of Neurology, Philipps Universitat, Baldingerstrasse, D 35043 Marburg, Germany
    Parkinsonism Relat Disord 19:37-42. 2013
    Although dopamine agonists (DAs) are sometimes perceived as poorly tolerated by the elderly, there is little clinical evidence to support these concerns...
  64. ncbi Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood
    Pasquale Montagna
    Dipartimento di Scienze Neurologiche, Universita degli Studi di Bologna, Bologna, Italy
    Sleep Med 12:34-40. 2011
    ..We investigated the change of RLS-related mood impairment during treatment of RLS with pramipexole, a dopamine D(3)/D(2) agonist...
  65. ncbi Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925
    Ariel Graff-Guerrero
    PET Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Int J Neuropsychopharmacol 13:273-87. 2010
    ..Thus, [11C](+)-PHNO seems a suitable PET radiotracer to estimate D3 receptor occupancy in humans...
  66. ncbi Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists
    Frank Andersohn
    Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany
    Mov Disord 24:129-33. 2009
    There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse...
  67. ncbi Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease
    Mark Sanford
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    CNS Drugs 25:699-719. 2011
    ....
  68. ncbi Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease
    K Kujawa
    Department of Neurological Sciences, Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
    Arch Neurol 57:1461-3. 2000
    ..To study the frequency and severity of acute orthostatic hypotension (OH) in patients with Parkinson's disease who are starting dopamine agonist therapy...
  69. ncbi The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review
    Albert F G Leentjens
    Department of Psychiatry, Maastricht University Medical Centre, Maastricht, The Netherlands
    Drugs 71:273-86. 2011
    ..Currently, dopamine agonists are being suggested as an alternative to antidepressants for the treatment of depression in PD...
  70. ncbi Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results
    F Stocchi
    Department of Neurosciences, University of Rome La Sapienza, Italy
    Neurol Sci 22:93-4. 2001
    ..Continuous dopaminergic stimulation can be achieved more easily by infusing dopamine agonists subcutaneously...
  71. pmc Novelty seeking behaviour in Parkinson's disease
    Atbin Djamshidian
    Department of Molecular Neuroscience and Reta Lila Weston Institute for Neurological Studies, University of London, London, United Kingdom
    Neuropsychologia 49:2483-8. 2011
    ..Our findings suggest that attraction to novelty is a personality trait in all PD patients with ICBs which is independent of medication status...
  72. ncbi Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies
    Jan Peer Elshoff
    UCB Pharma, UCB BiosciencesGmbH, Alfred Nobel Str 10, Monheim am Rhein, Germany
    Clin Ther 34:966-78. 2012
    ..The dopamine agonist rotigotine is formulated in a transdermal delivery system (patch) for once-daily application. It has been reported as efficacious in the treatment of idiopathic Parkinson's disease (PD) and restless legs syndrome...
  73. ncbi Combinatorial topography and cell-type specific regulation of the ERK pathway by dopaminergic agonists in the mouse striatum
    Giuseppe Gangarossa
    INSERM U661, Montpellier, France
    Brain Struct Funct 218:405-19. 2013
    ..This work evidences the need of a precise identification of the striatal areas under study to further understand striatal plasticity...
  74. ncbi Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease
    John D McCorvy
    Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy and Integrative Neuroscience Program, Purdue University, West Lafayette, IN 47907, USA
    Psychopharmacology (Berl) 222:81-7. 2012
    ..Recently, we discovered doxanthrine (DOX), an oxygen bioisostere of DHX that has even greater selectivity for the D₁ dopamine receptor...
  75. ncbi Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain
    Gráinne C O'Keeffe
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Cell Cycle 8:2888-94. 2009
    ..This result has implications for the use of dopaminergic therapies in PD and in the development of such therapies focusing on upregulating SVZ neurogenesis...
  76. ncbi Three cases of delusional parasitosis caused by dopamine agonists
    S Flann
    Department of Dermatology, Orpington Hospital, Orpington, Kent, UK
    Clin Exp Dermatol 35:740-2. 2010
    We report three cases of delusional parasitosis (DP) in patients with well-established Parkinson's disease, all of whom were taking dopamine agonists. In all three cases, the DP resolved rapidly when the drug was withdrawn.
  77. pmc Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
    Muriel Babey
    Department of Neurosurgery, University of Berne, Inselspital, 3010, Berne, Switzerland
    Pituitary 14:222-30. 2011
    ..5 months. Patients with small prolactinomas can safely consider pituitary surgery in a specialized centre with good chance of long-term remission as an alternative to long-term DA therapy...
  78. ncbi Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease
    Robert B McCall
    Pfizer, Inc, Kalamazoo, MI 49007, USA
    J Pharmacol Exp Ther 314:1248-56. 2005
    ..In summary, sumanirole is the first published selective D(2) receptor agonist. The compound has activity in animal models of dopamine hypofunction and has a high level of efficacy in animal models of Parkinson's disease...
  79. ncbi A novel dopamine agonist for the transdermal treatment of Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, Guy s, King s and St Thomas School of Biomedical Sciences, King s College, London, United Kingdom
    Neurology 65:S3-5. 2005
    ..The pharmacologic properties of rotigotine suggest that it has the characteristics necessary to form the basis of a transdermal treatment for the control of motor symptoms of PD...
  80. ncbi Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials
    Jaime Kulisevsky
    Unit of Movement Disorders, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Drug Saf 33:147-61. 2010
    b>Dopamine agonists have a well established role in the treatment of Parkinson's disease. The choice of a particular dopamine agonist requires assessing the benefit-risk balance of each available medication.
  81. ncbi Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage
    Ju Hee Lim
    College of Pharmacy and Research Institute of Drug Development, Chonnam National University, 300 Yongbong Dong, Buk Gu, Gwangju 500 757, South Korea
    Pharmacol Res 57:325-31. 2008
    ..Taken together, we investigate the novel cytoprotective effect of bromocriptine involving PI3K- and Nrf2-mediated upregulation of the antioxidant enzyme NQO1...
  82. pmc Burning mouth syndrome responsive to pramipexol
    J Stuginski-Barbosa
    The Department of Neurology, School of Medicine at Ribeirao Preto, Ribeirao Preto, SP, Brazil
    J Headache Pain 9:43-5. 2008
    ..We discuss potential pathophysiological implications of our findings...
  83. ncbi Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom
    Virginie Czernecki
    Center d Investigation Clinique, Federation de Neurologie, INSERM Unit 679, Paris, France
    Mov Disord 23:964-9. 2008
    ....
  84. ncbi Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease
    Dirk Deleu
    College of Medicine, Sultan Qaboos University, PO Box 35, Al Khod, Sultanate of Oman
    Clin Pharmacokinet 41:261-309. 2002
    ..Drugs for which there is at least some evidence for neuroprotective effect are certain dopamine agonists, amantadine and MAO-B inhibitors (selegiline)...
  85. ncbi Tremor and dopamine agonists
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL 62794 9643, USA
    Neurology 58:S57-62. 2002
    ..Comparable improvement is achieved with the dopamine agonists. Dopamine agonists are particularly well suited for patients with newly diagnosed tremor-predominant disease ..
  86. pmc Investigation of D₂ receptor-agonist interactions using a combination of pharmacophore and receptor homology modeling
    Marcus Malo
    Department of Chemistry, Medicinal Chemistry, University of Gothenburg, 41296 Goteborg, Sweden
    ChemMedChem 7:471-82, 338. 2012
    ..The strategy has the potential to identify weaknesses in the individual models and thereby provides an opportunity to improve the discriminating predictivity of both pharmacophore searches and structure-based virtual screens...
  87. pmc Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors
    Julie A Przybyla
    Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA
    Eur Neuropsychopharmacol 19:138-46. 2009
    ..These findings demonstrate a reversed stereoselectivity for the enantiomers of DOX at D(1) and alpha(2C) receptors and have implications for the therapeutic utility of doxanthrine...
  88. ncbi Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes
    Richard Scranton
    Veroscience LLC, 1334 Main Road, Tiverton, RI 02878, USA
    Expert Opin Pharmacother 11:269-79. 2010
    ..The quick-release formulation of bromocriptine (bromocriptine-QR; Cycloset) represents such a therapy...
  89. pmc The time course of dopamine transmission in the ventral tegmental area
    Christopher P Ford
    Vollum Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Neurosci 29:13344-52. 2009
    ..Thus, dopamine transmission in the midbrain is more localized then previously proposed...
  90. ncbi Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome
    Sergio Reis Soares
    Instituto Valenciano de Infertilidad, IVI Lisboa Av Infante Dom Henrique, 333 H, 1800 282 Lisbon, Portugal
    Hum Reprod Update 14:321-33. 2008
    ..Ovarian hyperstimulation syndrome (OHSS) typically occurs when ovaries are primed with FSH/LH and subsequently exposed to hCG. The ultimate pathophysiological step underlying this clinical picture is increased vascular permeability (VP)...
  91. ncbi Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor
    Nuska Tschammer
    Department of Chemistry and Pharmacy, Friedrich Alexander University, Erlangen, Germany
    Mol Pharmacol 79:575-85. 2011
    ..Overall, the residue His393(6.55) and proximate molecular substructures of receptor ligands were identified to be crucial for multidimensional ligand efficacy...
  92. ncbi Efficacy and safety of dopamine agonists in traumatic brain injury: a systematic review of randomized controlled trials
    Anne Julie Frenette
    Department of Pharmacy, Hopital du Sacre Coeur de Montreal, Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada
    J Neurotrauma 29:1-18. 2012
    In the intensive care unit, dopamine agonists (DA) have been used in traumatic brain injury (TBI) patients to augment or accelerate cognitive recovery and rehabilitation...
  93. ncbi Effects of acute and chronic apomorphine on sex behavior and copulation-induced neural activation in the male rat
    Jocelien D A Olivier
    Department of Anatomy, UMC St Radboud, University of Nijmegen, The Netherlands
    Eur J Pharmacol 576:61-76. 2007
    ....
  94. ncbi Practical considerations in the use of apomorphine injectable
    Annette Bowron
    Jubilee Day Hospital, North Tyneside General Hospital, Tyne and Wear, United Kingdom
    Neurology 62:S32-6. 2004
    ....
  95. ncbi Mechanisms of ligand binding and efficacy at the human D2(short) dopamine receptor
    Sarah L Payne
    School of Animal and Microbial Sciences, University of Reading, UK
    J Neurochem 82:1106-17. 2002
    ....
  96. ncbi Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists
    Lisa M Neff
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Tufts New England Medical Center, Boston, MA 02111, USA
    Pituitary 10:81-6. 2007
    Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients ..
  97. ncbi Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo
    Rajesh Narendran
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York 10032, USA
    Synapse 60:485-95. 2006
    ..This property might contribute to its higher vulnerability to endogenous DA compared to [11C]raclopride and [11C]NPA...
  98. ncbi Clinical practice. Prolactinoma
    Janet A Schlechte
    Department of Internal Medicine, University of Iowa, Iowa City, USA
    N Engl J Med 349:2035-41. 2003
  99. pmc Ovarian hyperstimulation syndrome: pathophysiology and prevention
    Carolina O Nastri
    Departamento de Ginecologia e Obstetrícia da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo DGO HC FMRP USP, Avenida dos Bandeirantes 3900, 8 masculine Andar, Ribeirao Preto, Sao Paulo, Brazil, CEP 14049 900
    J Assist Reprod Genet 27:121-8. 2010
    ..To review and discuss the pathophysiology and prevention strategies for ovarian hyperstimulation syndrome (OHSS), which is a condition that may occur in up to 20% of the high risk women submitted to assisted reproductive technology cycles...
  100. ncbi The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells
    J E de Leeuw van Weenen
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    Biochem Pharmacol 79:1827-36. 2010
    ..We suggest that treatment with bromocriptine promotes beta cells rest, thereby preventing long-lasting hypersecretion of insulin and subsequent beta cell failure...
  101. ncbi Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table
    Katherine Grosset
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom
    Mov Disord 19:1370-4. 2004
    Of 99 patients on ergot-derived dopamine agonists informed about possible long-term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%...

Research Grants63

  1. Enzymatic Regulation of S-Glutathionylation : Role in Apoptosis and Disease
    John J Mieyal; Fiscal Year: 2012
    ..Increased knowledge of how these enzymes regulate the balance between cell survival and cell death will promote innovative therapeutic development. ..
  2. Prolactin as a Growth Factor in Breast Cancer
    Nira Ben-Jonathan; Fiscal Year: 2013
    ..Aim 4: To establish mixed-cultures of fully differentiated LS14 adipocytes and BCC and examine whether dopamine agonists sensitize LS14/BCC tumors in athymic mice to anticancer drugs...
  3. ULTRASTRUCTURE OF MESOLIMBIC TRANSMITTER INTERACTIONS
    Virginia M Pickel; Fiscal Year: 2012
    ..abstract_text> ..
  4. Dopamine and the Role of Anterior Cingulate Cortex in Executive Processes
    Benjamin Y Hayden; Fiscal Year: 2013
    ..Given the prominence of the Platt Lab and of Duke University, this is an ideal environment to perform the research described in this application. ..
  5. Rapid-onset Dystonia Parkinsonism (DYT12 Dystonia): Pathophysiology &Atp1a3 Mice
    Yuqing Li; Fiscal Year: 2011
    ....
  6. PHARMACOLOGY AND PHYSIOLOGY OF RETINAL GANGLION CELLS
    Andrew T Ishida; Fiscal Year: 2013
    ....
  7. A novel rodent model of dopamine agonist-induced impulsive control disorders
    T Celeste Napier; Fiscal Year: 2012
    ..Moreover, we predict this model will provide a completely new means to rapidly screen compounds under development as therapeutics for CNS disorders for potential of the compound to induced ICDs. ..
  8. Correction of obesity by optogenetic manipulation of striatal neurons
    ELIZABETH KATHERINE SCHWARTZ; Fiscal Year: 2013
    ..Observations made in the clinical as well as the laboratory over the past few decades have shown that dopamine agonists often cause weight loss and decreased food reward, whereas dopamine antagonists often lead to weight gain (..
  9. Cocaine effects on neurons
    John T Williams; Fiscal Year: 2013
    ....
  10. Dopamine Effects on Mesocorticolimbic Function in Parkinson Disease
    DANIEL OLIVER CLAASSEN; Fiscal Year: 2013
    ..Future studies will therefore focus on optimizing cognitive performance in PD patients, providing a basis for improved individulalized therapy for patients with PD. ..
  11. INHIBITORY DEFICITS IN HUMAN AND ANIMAL MODELS OF BIPOLAR DISORDER
    William Perry; Fiscal Year: 2013
    ..Completion of this work will assist in understanding the underlying brain dysfunction of BD as well as assist in discovering and developing novel treatments. ..
  12. NOVEL SECOND MESSENGER SIGNALING IN THE STRIATUM
    Ann M Graybiel; Fiscal Year: 2013
    ..The work proposed is highly significant for understanding signaling in key basal ganglia neurons whose function is essential for normal behavior and whose dysfunction leads to major extrapyramidal disorders. ..
  13. Adjunct Aripiprazole for Symptomatic Hyperprolactinemia in Female Schizophrenia
    Deanna L Kelly; Fiscal Year: 2013
    ..There is little evidence to guide treatment in this important area however dopamine agonists such as bromocriptine or amantadine may exacerbate symptoms, have lacking efficacy data and are associated ..
  14. Determining the role of dopamine D2L versus D2S receptors in vivo
    Emiliana Borrelli; Fiscal Year: 2013
    ..Thus expanding our scientific knowledge of dopamine-mediated responses and providing crucial information for pharmacological designing of D2-targeted drugs. ..
  15. Apathy in Alzheimer's Disease Methylphenidate Trial
    Paul B Rosenberg; Fiscal Year: 2010
    ..for future studies to understand the mechanisms involved in the effects of methylphenidate and other dopamine agonists on apathy...
  16. Functional Selectivity: A Novel approach for CNS Drug Discovery
    Bryan L Roth; Fiscal Year: 2013
    ..abstract_text> ..
  17. Dopaminergic Modulation Of Cognitive Aspects Of Skill Acquisition In PD
    Brenda Hanna Pladdy; Fiscal Year: 2010
    ..symptoms in PD are not well recognized in clinical practice and it is uncertain how current treatments with dopamine agonists affect cognition...
  18. Gating and Inhibiting in Schizophrenia
    David L Braff; Fiscal Year: 2013
    ..underlying IB deficits by: 1) assessing the impact of neuregulin-1 fragments on the IB deficits induced by dopamine agonists and NMDA antagonists in rats and mice;2) assessing IB deficits in interneuron-specific ErbB4 "knock out" ..
  19. The neurogenic potential of cholinergic activation in AD.
    ELIZABETH ADAMS ECKMAN; Fiscal Year: 2013
    ..abstract_text> ..
  20. CATECHOLAMINES AND SEROTONIN IN BLOOD PRESSURE CONTROL
    Curt Freed; Fiscal Year: 1991
    ..Serotonin agonists, alpha-2 receptor agonists and dopamine agonists have all been shown to lower blood in hypertensive animals...
  21. DEVELOPMENT OF POTENTIALLY SELECTIVE DOPAMINE AGONISTS
    David E Nichols; Fiscal Year: 2010
    ..Our work will generate molecular probes that should help to increase our understanding of these pathways, and may also provide new therapies for disorders such as Parkinson's disease and schizophrenia. ..
  22. Receptor trafficking profiles of clinically important dopaminergic drugs
    Jennifer L Whistler; Fiscal Year: 2013
    ....
  23. Dopamine D2/D3 Receptors in Compulsive Disorders
    James H Woods; Fiscal Year: 2012
    ..The behavioral pharmacology of these models will be tested with various dopamine agonists and antagonists, and the roles of sensitization, goal-tracking, and sign-tracking will be studied...
  24. Continuation of NET-PD Trials at University of Miami Miller School of Medicine
    Carlos Singer; Fiscal Year: 2013
    ..multi-center, double blind, placebo controlled trial tested against the background of dopaminergic therapy (dopamine agonists and levodopa) and best PD care...
  25. Extrastriatal functions of dopamine
    THOMAS N WICHMANN; Fiscal Year: 2013
    ....
  26. METABOTROPIC GLUTAMATE RECEPTORS IN THE BASAL GANGLIA
    Colleen M Niswender; Fiscal Year: 2013
    ..Additionally, we will test the hypothesis that mGlu8 PAMs, like mGlu8 agonists, have anti-PD effects in rodent models of prolonged dopamine depletion. ..
  27. Long-term effects of early-life antipsychotic drug treatment
    MARK EDWARD BARDGETT; Fiscal Year: 2011
    ..gating during adulthood, and whether early-life risperidone heightens the sensitivity of these behaviors to dopamine agonists, enhances impulsivity, and disrupts forebrain dopamine release in adulthood...
  28. REGULATION OF MOTOR FUNCTION IN PARKINSON'S DISEASE
    Stella M Papa; Fiscal Year: 2013
    ..We will use glutamate antagonists in striatal infusions to examine the responses to selective dopamine agonists in external pallidal neurons...
  29. Sleepiness in Parkinson's Disease
    Seiji Nishino; Fiscal Year: 2013
    ..The results of the study will determine the major factor(s) contributing to the D2/3 agonist induced pathological sleepiness in PD, and prove informative in preventing/treating this life-threatening, disabling disease. ..
  30. QUANTITATIVE DOPAMINE RECEPTOR PHARMACODYNAMICS FROM FMRI
    Kevin J Black; Fiscal Year: 2010
    ..The proposed experiments will test the model with dopamine agonists (SKF82958, pramipexole)...
  31. VALIDATION OF NEUROIMAGING BIOMARKERS FOR NIGROSTRAITAL NEURONS
    JOEL SYNES PERLMUTTER; Fiscal Year: 2013
    ..This study will provide the critical tools for targeting the relevant pathologic sites for testing new therapies for PD. ..
  32. AUTORECEPTOR REGULATION OF DOPAMINE RELEASE
    Greg Gerhardt; Fiscal Year: 1991
    ..of dopamine release in these five brain regions by performing dose response curves with the D2 selective dopamine agonists, pergolide and quinpirole; the D1 selective dopamine agonist SKF 38393; the non- selective dopamine ..
  33. The prefrontal cortex in salience and control in cocaine addiction: phFMRI study
    Rita Z Goldstein; Fiscal Year: 2012
    ..Thus, using the pharmacological functional activation and behavioral results in our study, we may be able to highlight the intervention approaches that may be most beneficial. ..
  34. Synaptic Transmission, Plasticity and Integration in the Subthalamic Nucleus
    Mark D Bevan; Fiscal Year: 2010
    ..abstract_text> ..
  35. Cognitive impact of cocaine cues and agonist treatment approaches
    Charles W Bradberry; Fiscal Year: 2013
    ..Aim 4) Determine if treatment with a low dose of the indirect dopamine agonist amphetamine improves attentional control concomitant with improved deactivation of the default mode network measured by CMRglc. ..
  36. The Neurobehavioral Processes of Motor Inhibition
    KRISTINA ANNE NEELY; Fiscal Year: 2012
    ..research program, which is to understand how antiparkinson treatments such as deep brain stimulation and dopamine agonists alter the neural mechanisms underlying action inhibition...
  37. Subtype Specific Agonists for D1-D5 Dopamine Receptors
    William Goddard; Fiscal Year: 2007
    ..receptors can induce side effects similar to those resulting from dopamine depletion, and high doses of dopamine agonists can cause psychoses...
  38. Developmental Psychopharmacology of Antipsychotics
    JENNY WILEY; Fiscal Year: 2007
    ..to challenges with dopaminergic agents in later life such that animals are more sensitive to the effects of dopamine agonists and less sensitive to those of dopamine antagonists...
  39. MECHANISMS GOVERNING ONSET OF OVARIAN FUNCTION
    Kathleen Ryan; Fiscal Year: 1990
    ..Thus an added tool is available to allow the distinction of somatic changes from pubertal changes, and the separation of photoperiod specific changes from puberty specific ones - a truly exciting prospect...
  40. Translational Research of Cocaine, Striatum, and Impulsivities
    Marc N Potenza; Fiscal Year: 2013
    ..Together, data from these highly integrated, translational studies should advance our understanding of CD and help target the development of more effective prevention and treatment strategies. ..
  41. Medications for Comorbid Cocaine and Alcohol Dependence
    Rolley Johnson; Fiscal Year: 2002
    ..Over the past decade, medications including dopamine agonists, antagonists, tricyclic antidepressants, selective serotonin reuptake inhibitors, opiate mixed agonist-..
  42. REGULATION OF PROLACTIN SECRETION AT THE LACTOTROPH
    JOEL TABAK-SZNAJDER; Fiscal Year: 2013
    ..For example, the benign hypersecreting pituitary tumor known as a prolactinoma is treated with the dopamine agonists bromocryptine or cabergoline...
  43. A Genetic Test for Drug-Induced Dyskinesia Risk Determination
    Abraham Kovoor; Fiscal Year: 2007
    ..In addition, the ability to estimate dyskinesia risk will be very valuable in the development of new and improved antipsychotic and antiparkinsonian drugs. [unreadable] [unreadable] [unreadable] [unreadable]..
  44. STARTLE GATING AND LOCOMOTION IN D2-FAMILY KNOCKOUT MICE
    Mark Geyer; Fiscal Year: 2004
    ..habituation, and prepulse inhibition; (3) characterize the effects of amphetamine and selected direct dopamine agonists on the same measures; (4) characterize the effects of amphetamine and selected direct dopamine agonists on ..
  45. SELF-INJURIOUS BEHAVIOR: MOLECULAR MARKERS
    DARRAGH DEVINE; Fiscal Year: 2002
    ....
  46. Neurobiology of Nicotine: Hormones and Behavior
    NANCY MELLO; Fiscal Year: 2007
    ..An increased understanding of nicotine's acute effects on anterior pituitary, gonadal and adrenal hormones may suggest new strategies for the development of antinicotine medications as it has for cocaine. ..
  47. Regulation and function of Nurr1 in adult nigrostriatal dopamine neurons
    JEFFREY EELLS; Fiscal Year: 2009
    ....
  48. BASAL GANGLIA GABA-DOPAMINE INTERACTIONS
    James Bennett; Fiscal Year: 1990
    ....
  49. ON-OFF MOOD CHANGE IN PARKINSONS DISEASE
    Kevin Black; Fiscal Year: 2000
    ..The localized effects of specific dopamine agonists on cerebral blood flow (rCBF) measured with PET will be used to indicate changes in neuronal activity...
  50. Parkinson's Disease Neuroprotection Clinical Center
    Charles Adler; Fiscal Year: 2005
    ..levodopa, dopamine agonists)...
  51. NON-NITROGEN AND NITROGEN CONTAINING DOPAMINE DRUGS
    Duane Miller; Fiscal Year: 1992
    ..4.To synthesize a set of formamidino, guanidino and thiourea analogs of DA, in order to investigate the overall importance of hydrogen bonding in the interaction of DAergic drugs with DAergic receptors...
  52. PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL CENTER
    Bala Manyam; Fiscal Year: 2005
    ..abstract_text> ..
  53. NUCLEUS ACCUMBENS, COCAINE REWARD & RECOVERY
    RONALD HAMMER; Fiscal Year: 1993
    ..The therapeutic potential of dopamine agonists on metabolic recovery during abstinence will be evaluated, allowing a better understanding of beneficial ..
  54. SCIENTIST DEVELOPMENT AWARD FOR A CLINICIAN
    Kyle Kampman; Fiscal Year: 1999
    ....
  55. MOLECULAR REGULATION OF D1 DOPAMINE RECEPTOR FUNCTION
    Richard Mailman; Fiscal Year: 2004
    ..These studies of beta-arrestin binding and recruitment will provide another functional endpoint in the delineation of the molecular mechanisms of D1 receptor desensitization. ..
  56. Efficacy of Amantadine Hydochloride after Pediatric TBI
    SUE BEERS; Fiscal Year: 2002
    ..This information will optimize the design of Phase III clinical trials. ..
  57. Acceptability of pharmacologic treatment for methamphetamine dependence among MSM
    Grant Colfax; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  58. MODEL OF SCHIZOPHRENIA GATING DEFICITS: NMDA EFFECTS
    Robert Mansbach; Fiscal Year: 1991
    ..PCP produces deficits in PPI similar to those seen in schizophrenic patients and in animals treated with dopamine agonists. Specifically, we intend to isolate the receptor component responsible for PPI deficits through the testing ..
  59. AMANTADINE FOR TREATMENT OF COCAINE DEPENDENCE
    Leonard Handelsman; Fiscal Year: 1992
    ..circuitry and the characterization of the self-administration of cocaine in animal models indicate that dopamine agonists may be useful agents for the attenuation of cocaine craving and use in humans...
  60. PSYCHOPHARMACOLOGY OF DA AGONIST CNS EFFECTS
    LOUIS CHIODO; Fiscal Year: 1993
    ....
  61. Cocaine and Polydrug Abuse: New Medication Strategies
    NANCY MELLO; Fiscal Year: 2006
    ..treatment with potential anti-cocaine medications (endocrine modulators, dopamine reuptake inhibitors; dopamine agonists and antagonists ) and anti-opioid medications (high and intermediate efficacy mu agonists and a new long-..
  62. Inhaled dopamine agonists for late stage Parkinsonism
    Patrik Munzar; Fiscal Year: 2005
    ..The aim of this project is to develop an inhalation device that delivers dopamine agonists rapidly into the blood stream in a convenient, non-invasive fashion...
  63. Inhaled dopamine agonist for late stage Parkinsonism
    Joshua Rabinowitz; Fiscal Year: 2003
    ..The most effective pharmacological treatments for "off' periods are dopamine agonists, with the dopamine agonist apomorphine especially effective...